Alfural

Quick links to important sections

Alfural

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Alfural

Quick Facts

Property Description
Active ingredient Alfuzosin hydrochloride
Form Extended-release tablet
Pharmacological class Alpha-adrenoreceptor antagonist (alpha blocker)
General purpose Relieving lower urinary tract discomfort
Origin Synthetic, Quinazoline derivative

What Type of Medicine is Alfural (Alfuzosin)?

Alfural is a prescription-only medication that utilizes the active ingredient Alfuzosin hydrochloride, which is a synthetic quinazoline derivative. It belongs to the high-level pharmacological class of alpha-adrenoreceptor antagonists, often referred to as alpha blockers. This medication is a single-component product presented as an extended-release tablet intended for oral administration. This specific sustained-release formulation is designed to deliver the active compound gradually, helping to provide a consistent therapeutic effect over a prolonged period.


What is the General Purpose of This Alpha Blocker?

Because of its classification, the general purpose of Alfuzosin is to relieve obstructive urinary symptoms by reducing mechanical resistance within the urinary pathway. As an alpha1-adrenergic antagonist, the drug acts to cause the selective relaxation of smooth muscle tissue. This effect specifically targets the smooth muscles found in the prostate gland and the bladder neck. Medications within this class diminish urethral tone. This means the medication helps ease discomfort and difficulty by relaxing the tissues that obstruct the flow of urine, serving the overall goal of improving function through the lower urinary tract.

What side effects are possible with Alfural?

Possible Side Effects and Safety Information

Alfural (Alfuzosin) has a documented safety profile based on its classification as an alpha-adrenoreceptor antagonist, with adverse reactions formally categorized by frequency and the affected body system in regulatory documents.

Frequency-Classified Adverse Reactions

Adverse effects are grouped by their incidence rates observed in clinical use:

  • Common Reactions (affecting up to 1 in 10 patients) typically include dizziness, headache, fatigue (asthenia), and gastrointestinal effects like nausea and abdominal pain.
  • Uncommon Reactions (affecting up to 1 in 100 patients) may involve postural hypotension (a drop in blood pressure upon standing), syncope (fainting), vertigo, palpitations, and rash.

Serious Adverse Reactions and Special Safety Notes

Specific serious adverse reactions are highlighted in official labeling, including the potential for Priapism (a persistent, painful erection) and Intraoperative Floppy Iris Syndrome (IFIS), a complication observed during cataract surgery. Liver injury, including cholestatic and hepatocellular damage, has been reported in post-marketing surveillance.

Certain effects, such as dizziness and asthenia, are officially documented as more likely to occur at the beginning of treatment.

Population-Specific Safety Constraints

The medicine is contraindicated (should not be used) in individuals with moderate or severe hepatic impairment. Caution is also required for patients with severe renal impairment. The medication is not indicated for use in the pediatric population.

Overdose and Emergency Response

Overdose and When to Seek Help

The primary clinical manifestation of Alfuzosin overdose, as documented in official regulatory labeling, is hypotension (low blood pressure) and the potential complications that result from severe cardiovascular depression. The official profile for Alfural overdose is focused on recognizing this systemic effect and enacting immediate, required supportive care.

When to Seek Immediate Medical Attention

Regulatory documents mandate that individuals who suspect an overdose must immediately contact a poison control center, see a doctor, or go to the nearest hospital emergency department. This action is required even if there are no immediate signs of discomfort or poisoning. Furthermore, urgent medical intervention is required for the specific manifestation of Priapism—a painful erection lasting more than four hours—which necessitates immediate cessation of the drug and emergency help.

Official Overdose Management

If an overdosage occurs, hospitalization is necessary for continuous monitoring and management. The official management procedures described in regulatory labeling are symptomatic and supportive, focusing on correcting the hypotension. These measures include keeping the patient in the supine position, instituting vascular filling (fluid administration), and providing vasopressor treatment to raise blood pressure. In cases of significant hypotension, a vasoconstrictor agent that acts directly on the vascular muscle fibers may be used. Due to its high protein binding, Alfuzosin is officially stated as not dialysable.

Population-Specific Overdose Note

While overdose severity may not be classified differently, regulatory information indicates that the risk of hypotension is generally greater in elderly patients.

Therapeutic Uses of Alfural

Main Uses and Benefits of Alfural

Alfural is a medication primarily prescribed to manage the clinical symptoms associated with benign prostatic hyperplasia (BPH), a common condition involving the non-cancerous enlargement of the prostate gland.

Treatment of Benign Prostatic Hyperplasia (BPH)

The primary application of Alfural is to improve urinary flow and reduce the symptoms caused by an enlarged prostate. As the prostate gland grows, it can exert pressure on the urethra, leading to various lower urinary tract symptoms. Alfural works by relaxing the smooth muscles in the prostate and the bladder neck, which helps to alleviate the obstruction of urine flow.

Key symptoms that Alfural helps manage include:

  • Urinary Hesitancy: Difficulty starting the flow of urine.
  • Weak Stream: A reduction in the force or volume of the urinary stream.
  • Frequency and Urgency: An increased need to urinate, often occurring suddenly.
  • Nocturia: The frequent need to wake up during the night to urinate.
  • Incomplete Emptying: The sensation that the bladder is not entirely empty after urination.

Benefits for Quality of Life

By addressing the physical symptoms of BPH, Alfural can contribute to a significant improvement in a patient’s daily comfort. The reduction in urinary frequency and the easing of the effort required to urinate can lead to better sleep patterns and reduced disruption of daily activities.

Clinical Role

While Alfural effectively manages the symptoms of BPH, it does not shrink the physical size of the prostate. Instead, it focuses on functional improvement by reducing muscle tension within the urinary tract. It is often utilized as a long-term management strategy to maintain urinary function and prevent the progression of bothersome symptoms.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Alfural (Alfuzosin) is authorized for use only in adult males for the treatment of symptoms associated with benign prostatic hyperplasia (BPH).

Populations Who Must Not Use Alfural (Contraindications)

The medicine is formally contraindicated in patients with a known hypersensitivity or allergy to alfuzosin or other quinazoline derivatives, such as terazosin or doxazosin. Use is also strictly prohibited in individuals with moderate or severe hepatic impairment (liver disease) or a history of orthostatic hypotension (low blood pressure upon standing).

Furthermore, Alfural must not be used concurrently with other alpha-1 adrenergic antagonists or with potent CYP3A4 inhibitors (e.g., ketoconazole, ritonavir), as this combination significantly increases Alfural exposure.

Populations Requiring Conditional Use

  • Severe Renal Impairment: Caution must be exercised when administering Alfural to patients with severe renal impairment (creatinine clearance le 30 mL/min), as safety data in this specific group are limited.
  • Cardiovascular Conditions: Caution is necessary for patients with QT prolongation (acquired or congenital) and for those taking antihypertensive medication. Treatment must be discontinued if symptoms of angina pectoris appear or worsen.
  • Pediatric Use: Alfural is not indicated for use in children or adolescents, as safety and efficacy have not been established in the pediatric population.

What should I know about interactions with other medicines?

Interactions with other medicines and products for Alfuzosin

Alfuzosin's interaction profile is significantly defined by its metabolism and its pharmacodynamic effects on blood pressure. This section outlines officially documented combinations and co-administration constraints.

Contraindicated Combinations

Substance Category Reason for Contraindication
Potent CYP3A4 Inhibitors (e.g., Ketoconazole, Itraconazole, Ritonavir) Significant increase in Alfuzosin plasma concentrations (AUC) and exposure.
Other Alpha-1 Blockers (e.g., Tamsulosin, Doxazosin) Severe risk of enhanced orthostatic hypotension.

Caution Required for Co-Administration

Caution is advised when co-administering with drugs that may enhance hypotensive effects or prolong the QTc interval:

  • Antihypertensive Drugs & Nitrates: Increased risk of hypotension.
  • PDE5 Inhibitors (e.g., Sildenafil, Tadalafil): Increased risk of hypotension.
  • QTc-Prolonging Agents: Increased risk of QTc interval prolongation.
  • Moderate CYP3A4 Inhibitors (e.g., Diltiazem, Cimetidine): Can lead to moderately increased Alfuzosin exposure.

Other Interaction-Related Notes

  • General Anaesthetics: Withdrawal of Alfuzosin is typically recommended 24 hours prior to surgery due to the risk of blood pressure instability.
  • Food: Food intake is known to increase the absorption and exposure of Alfuzosin. Consistent administration, immediately after the same meal each day, is required to maintain steady drug levels.
  • Population Note: Alfuzosin is officially contraindicated in patients with moderate or severe hepatic impairment due to significantly reduced clearance and increased exposure.

Mechanism of Action

The action of Alfural is exerted by targeting and modulating the specific biological pathways that govern smooth muscle tone in the lower urinary tract. This action focuses on inhibiting the signal for contraction within the target pathways; the mechanism does not influence the anatomical size of the prostate.

Selective Blockade of alpha1-Adrenoceptors

The drug's primary action is the selective antagonism of post-synaptic alpha1-adrenoceptors, which are present on the smooth muscle of the prostate and bladder neck. Alfuzosin competitively inhibits the binding of the neurotransmitter norepinephrine at these sites, preventing the signal cascade that initiates muscle contraction. This molecular step modifies the sympathetic nervous system's influence on the target tissues.

Modulation of Urethral Tone

By blocking the contractile signal, Alfural initiates a physiological cascade that causes the smooth muscle in the affected region to relax. This relaxation reduces the physical tension, or urethral tone, and lowers the overall bladder outlet resistance. The physiological effect resulting from diminished mechanical obstruction is an increase in fluid flow rate through the prostatic urethra.

Mechanistic Scope and Limitations

While Alfuzosin is functionally uroselective, the mechanism is not strictly subtype-specific, and alpha1-adrenoceptors are also found on blood vessels. This inherent mechanistic constraint means the drug can also exert a secondary, systemic vasodilatory effect. Crucially, the mechanism addresses only the dynamic (muscle tension) component of obstruction, and does not alter the static (anatomical size) component of the prostate.

Dosage and Administration Information

Alfural (alfuzosin hydrochloride) is a medication provided as a 10 mg extended-release tablet intended strictly for oral administration. The official dosing regimen for symptoms of benign prostatic hyperplasia (BPH) is one 10 mg tablet once daily.


Administration Schedule and Constraints

Alfural must be taken with food and should be consumed immediately after the same meal each day. This specific timing is critical to ensure a consistent and intended absorption profile of the extended-release formulation.

It is a mandatory procedural condition that the tablet must be swallowed whole using a fluid; the tablet must not be crushed, chewed, split, or ground. Violating this constraint would compromise the controlled-release mechanism of the medicine.

Feature Official Dosing Principle
Standard Adult Dose One 10 mg tablet, once daily.
Frequency Once every 24 hours.
Timing Taken with food, immediately after the same meal.
Missed Dose Rule Skip the missed dose; do not double up for the next dose.

Treatment Duration and Specific Populations

Alfural is utilized in two distinct duration patterns. For BPH, the medication is generally designated for long-term use to manage symptoms. Conversely, when used as supportive management following an episode of acute urinary retention (AUR), the official regimen is a short course of 3 to 4 days. Regarding specific populations, the medication is not indicated for use in children. Furthermore, the 10 mg extended-release tablet is contraindicated in patients with moderate or severe hepatic impairment, as defined in official government labeling.

Recent Clinical Evidence

Evidence on Combination Therapy (Drug X + Drug Y)

The majority of studies explored the association between combining drug X with drug Y and changes in symptoms of condition Z. Studies evaluated the potential association between this combination and changes in patient comfort and acute episodes.

These findings suggest that drug X may be a research focus compared to drug Y alone for managing severe cases. Comparative data is limited. Research has explored the long-term exposure to the combination in adults, and collected data on adverse events.

Consult your healthcare provider regarding the appropriate initiation of any treatment.

Key Studies and Findings

An overview of 15 human studies, including 3 randomized controlled trials (RCTs), detailed the clinical findings of the drug X + Y pairing.

One key RCT detailed the time to symptom resolution for participants receiving the combination versus the control group. The study recorded the mean difference in the time to resolution between the combination and placebo groups. The study authors concluded that these results warrant further investigation.

Another meta-analysis focused on the effects of the combination in patients resistant to monotherapy (drug Y alone). This analysis explored outcomes for 800 patients across four international sites.

This information relates only to the studies reviewed; talk to your doctor about your treatment options.

Pediatric Studies (Under 18)

Evidence remains limited regarding the use of Drug X or Drug Y in patients under 18 years old. No large-scale RCTs have been published.

The available research consists mainly of small, retrospective case series. These case series examined the tolerability and safety of Drug X in children aged 6 to 12. They suggested that the compound's safety profile was monitored in the observed patient groups.

It is not yet clear whether the long-term effects differ in pediatric populations compared to adults. Further research is necessary to establish safety and appropriate dosing.

Frequently Asked Questions (FAQ)

Common questions about Alfural (FAQ)


Q: How quickly does Alfural usually start working?

Studies on Alfural show that the highest concentration of the active ingredient in the body is reached about 8 hours after the extended-release tablet is taken with food. The earliest measurable effects, such as an increase in the maximum urinary flow rate, have also been recorded around this 8-hour mark following the first dose.


Q: How long after starting Alfural can I expect to see its full effect?

Clinical trials evaluate the effects of the medication over periods of several weeks or months. Official information indicates that progressive improvements in lower urinary tract symptoms have been observed in studies at time points such as one month and three months after beginning treatment.


Q: How long does Alfural stay in your system?

The terminal half-life of the active ingredient in Alfural is officially documented as being approximately 7 to 17 hours. The extended-release formulation is designed to release the compound gradually and maintain its intended action consistently over the full 24-hour dosing interval.


Q: Does Alfural affect blood pressure?

Yes, as an alpha-1 blocker, Alfural can cause a general relaxing of smooth muscle, which includes the muscles in blood vessel walls. Regulatory documents note that this may result in a drop in blood pressure, especially when changing positions, which is medically known as postural hypotension.


Q: Does Alfural make you sleepy or affect driving?

Official product information notes that common side effects include dizziness and fatigue. Regulatory information states that individuals should be aware of the possibility of these effects, and the need for caution regarding tasks like driving or operating machinery has been noted.


Q: Can I drink coffee while taking Alfural?

Regulatory documents do not specifically mention an interaction with coffee or caffeine. However, the medicine must be taken with food for proper absorption, and it is important to note that the drug is known to interact with substances that can influence blood pressure, which may warrant discussion with a healthcare provider.


Q: Are there any common supplements that should be avoided with Alfural?

The body processes Alfural using the CYP3A4 enzyme, and official documents mandate avoiding strong inhibitors of this enzyme to prevent high drug exposure. Consequently, patients who use supplements may need to consult the full product labeling to determine if they contain strong CYP3A4-inhibiting properties, as these must be avoided.


Q: Is Alfural safe to take with alcohol?

Regulatory safety advisories note that combining Alfural with alcohol can enhance the blood pressure-lowering effect of the medicine. This interaction could increase the risk of symptoms like dizziness, lightheadedness, or fainting, and the importance of minimizing or avoiding the concurrent use of alcohol has been noted in official safety advisories.


Q: How does Alfural interact with other prescription drugs for high cholesterol?

Official drug interaction lists focus on strong inhibitors of the CYP3A4 enzyme, which is involved in Alfural's metabolism. Specific statins or other cholesterol-lowering drugs are not broadly listed as contraindicated, unless they are classified as strong CYP3A4 inhibitors.


Q: Does Alfural cause sensitivity to the sun?

Photosensitivity, or increased sensitivity to the sun, is not listed among the common side effects in the official product documents. However, rash is noted as an uncommon side effect, which may sometimes be related to sun exposure.


Q: Is Alfural a type of antibiotic?

No. Alfural is classified as an alpha-adrenoreceptor antagonist, commonly known as an alpha blocker. It works by relaxing smooth muscle in the urinary tract and is not an antibiotic, which is used to treat bacterial infections.


Q: Can Alfural be used for problems other than its main approved use?

Official regulatory documents, such as those from the FDA, state that the medication is indicated only for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH) in adult males. It is not indicated for treating other conditions like hypertension.


Q: What is Alfural's safety classification for use during pregnancy?

Alfural is indicated for use only in adult males. Regulatory authorities have not assigned a standard US FDA pregnancy category. However, in Australia, the drug is designated as Pregnancy Category B2, which describes agents where available data from human studies are limited, but have not suggested an increase in harm to the fetus when used by a small number of women.


Q: Is Alfural a controlled substance?

The active ingredient, alfuzosin, is not currently listed as a controlled substance under the schedules maintained by the U.S. Drug Enforcement Administration (DEA) or similar international bodies.


Q: Can Alfural cause weight gain or weight loss?

Changes in body weight are not listed as common or uncommon side effects in the official regulatory documents or clinical study reports for Alfural.


Q: Is there a generic version of Alfural available?

Yes. According to the FDA’s approved drug product information, generic versions of Alfuzosin hydrochloride extended-release tablets are available and are considered therapeutically equivalent to the brand name product.


Q: What research evidence supports the use of Alfural?

Clinical trials submitted to regulatory agencies demonstrated that Alfural produced statistically significant improvements in two key measures: the rate of urinary flow and overall BPH symptom scores in men, when compared to a placebo group.


Q: What is the difference between Alfural tablets and capsules?

Official product information states that Alfural is only manufactured and supplied as a 10 mg extended-release tablet for oral use. An alternative capsule formulation is not listed in the regulatory documents.


Q: What if I take too much Alfural by accident?

Regulatory documents indicate that the main concern following an accidental overdose is significant low blood pressure (hypotension). Treatment is supportive, often involving measures to help raise blood pressure, such as keeping the patient in a reclined position.


Q: Can I take Alfural if I have a history of [common contraindication, e.g., 'heart problems']?

Official safety information lists specific contraindications related to heart health, including a history of orthostatic hypotension or certain forms of QT prolongation. Caution is also noted for patients with pre-existing angina pectoris, where the medicine should be stopped if symptoms worsen.


Q: Does Alfural require a special prescription or monitoring?

Alfural is a prescription-only medication. Official patient counseling information emphasizes the need to monitor for signs of low blood pressure when standing (orthostatic hypotension), especially in patients with existing heart conditions or those who may have QT prolongation.


Q: Is Alfural gluten-free or suitable for people with allergies?

The medicine is contraindicated in patients with a known allergy to alfuzosin or other quinazoline derivatives. Clarification on a general 'gluten-free' status would require a review of the full inactive ingredient list (excipients) found in the specific product information.


Q: Does taking Alfural change any of my lab test results?

Official drug documentation does not typically indicate that Alfural interferes directly with common laboratory blood tests. However, its intended function as an alpha blocker means it can affect blood pressure measurements taken during patient visits.


Q: Are there different strengths of Alfural available?

No. Official regulatory documents list only one approved dosage strength for Alfural, which is the 10 mg extended-release tablet.


Q: Can I get Alfural without a prescription in some places?

According to regulatory information from major governing bodies, Alfural is designated strictly as a prescription-only medication in all jurisdictions covered by those authorities.


Q: Can Alfural make existing conditions worse?

Official safety documents explicitly warn that Alfural has the potential to cause the worsening of angina pectoris (chest pain) in individuals who already have coronary artery disease. If this occurs, treatment with the drug is generally discontinued.


Q: What is the shelf life of Alfural?

Regulatory approvals for Alfural tablets in their original, unopened packaging typically grant an approved shelf life of up to 5 years. This longevity is dependent on the product being stored precisely under the temperature and moisture-protection conditions specified in the official labeling.


Q: Is it normal to feel [common non-serious symptom] when first taking Alfural?

Regulatory documents officially note that side effects such as dizziness and asthenia (fatigue) are more likely to occur and be reported during the initial period after starting treatment.

How should Alfural be stored and disposed of?

Alfural (alfuzosin hydrochloride extended-release tablets) must be stored and disposed of according to official regulatory labeling to ensure product stability and safety.

Storage Requirements

Scope Item Official Regulatory Requirement
Storage Temperature Store at 25 C (77 F), with excursions permitted between 15 C and 30 C (59 F and 86 F) (Controlled Room Temperature).
Handling/Protection Keep in the container it came in, tightly closed, away from heat, moisture, and direct light. Keep from freezing (MedlinePlus).
Child Protection Keep out of the sight and reach of children.

Disposal Instructions

Official disposal is primarily through drug take-back programs. If no program is available, the product should be disposed of in the household trash by mixing the tablets with an undesirable substance (such as used coffee grounds or kitty litter) and placing the mixture into a sealed bag. Do not flush the product down the toilet or pour it into a drain unless specifically instructed by the regulatory documents. Scratch out all personal information on the prescription label before discarding the original container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Alfural found in:

A-Z Index: